A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To study the effect of mild, moderate, and severe renal impairment on the pharmacokinetics
(PK) of eliglustat.
Secondary Objective:
To assess the tolerability of eliglustat tartrate given as a single dose in subjects with
mild, moderate, and severe renal impairment in comparison with matched subjects with normal
renal function.